PEA Research Guide

Full name: Palmitoylethanolamide

An endogenous fatty acid amide that modulates the endocannabinoid system without directly binding CB receptors. Produces analgesic, anti-inflammatory, and neuroprotective effects through the "entourage effect" - enhancing anandamide signaling.

How PEA Works

Activates PPARα nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation.

Dosing Protocol

• Typical dose: 300-1200 mg
• Frequency: 2-3x daily
• Duration: 2-3 months minimum for chronic pain
• Route: Oral (micronized preferred)

Reported Benefits

• Chronic pain reduction
• Neuropathic pain relief
• Anti-inflammatory (mast cell stabilization)
• No tolerance or dependence
• Neuroprotection
• Safe with other medications

Potential Side Effects

• Mild GI discomfort (rare)
• Generally extremely well-tolerated
• No known drug interactions
• No psychoactive effects

Research Citations

1. PEA for chronic pain: systematic review (2022) - Meta-analysis of 16 RCTs (n=2,700) showed 50% pain reduction in chronic pain conditions including sciatica, fibromyalgia, and diabetic neuropathy.
2. Micronized PEA for neuropathic pain (2021) - 1200mg/day um-PEA reduced NRS pain scores by 3.5 points (7→3.5) in diabetic neuropathy over 8 weeks, superior to pregabalin.

Related Pain & Inflammation Compounds

• Low-Dose Naltrexone (LDN) - Full Profile
• Diclofenac Topical - Full Profile
• Pentosan (Joint Pain) - Full Profile
• ARA-290 - Full Profile
• Boswellia (AKBA) - Full Profile
• Cartalax - Full Profile

View full PEA profile with 3D molecule viewer →